Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response

被引：0
|
作者：
Cochin, Thomas [1 ]
Noal, Sabine [2 ]
Stefan, Dinu [1 ]
Bodet, Damien [3 ]
Rouger, Jeremie [3 ]
Dorbeau, Marine [4 ]
Neviere, Zoe [2 ]
机构：
[1] Ctr Francois Baclesse, Dept Radiat Oncol, Caen, France
[2] Ctr Francois Baclesse, Dept Sarcoma Oncol, Caen, France
[3] Ctr Hosp Univ, Dept Pediatry Oncol, Caen, France
[4] CTR FRANCOIS BACLESSE, DEPT PATHOL, CAEN, France
来源：
FRONTIERS IN ONCOLOGY | 2025年 / 14卷
关键词：
inflammatory myofibroblastic tumor; crizotinib; sequential treatment ALK-TKI; pediatric; ALK inhibitor; CRIZOTINIB; INVOLVEMENT; INHIBITORS; CERITINIB; LYMPHOMA; BRAIN; NSCLC; 2P23;
D O I：
10.3389/fonc.2024.1505257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Inflammatory myofibroblastic tumors (IMTs) are known to be associated with rearrangements of the anaplastic lymphoma kinase (ALK) gene. The treatment of this type of tumor includes systemic therapies such as chemotherapies or anti-inflammatories; in recent years, targeted anti-ALK therapies have emerged and became the standard of care in ALK rearranged patients. We aimed to present a rare case of musculoskeletal IMT with ALK rearrangement, characterized by metastatic evolution and enhanced responses to sequential treatment with all ALK-TKI. We have outlined a potential treatment pathway involving sequential ALK-TKI targeted therapies and successive local interventions to control the cancer.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
    Li, Mengmeng
    Xing, Ruyue
    Huang, Jiuyan
    Shi, Chao
    Wei, Chunhua
    Wang, Huijuan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor
    Bonvini, Paolo
    Rossi, Elisabetta
    Zin, Angelica
    Manicone, Mariangela
    Vidotto, Riccardo
    Facchinetti, Antonella
    Tombolan, Lucia
    Affinita, Maria Carmen
    Santoro, Luisa
    Zamarchi, Rita
    Bisogno, Gianni
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [3] Inflammatory Myofibroblastic Tumor of the Esophagus and Stomach Successfully Treated With ALK Inhibitor in a Pediatric Patient: A Case Report and Concise Review of Literature
    Billingsley, Benjamin C.
    Chaudhary, Ritica
    Morris, Michael W.
    Cox, Jennifer A.
    Camacho-Gomez, Sandra M.
    Varshney, Neha
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2025, 33 (01) : 145 - 152
  • [4] Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report
    Comandini, Danila
    Catalano, Fabio
    Grassi, Massimiliano
    Pesola, Guido
    Bertulli, Rossella
    Guadagno, Antonio
    Spina, Bruno
    Mascherini, Matteo
    De Cian, Franco
    Pistoia, Federico
    Rebuzzi, Sara Elena
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature
    Liu, Qiuyu
    Kan, Yunzhen
    Zhao, Yuewu
    He, Hui
    Kong, Lingfei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 15328 - 15332
  • [6] Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report
    Honda, Kazunori
    Kadowaki, Shigenori
    Kato, Kyoko
    Hanai, Nobuhiro
    Hasegawa, Yasuhisa
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 791 - 795
  • [7] Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
    Nagumo, Yoshiyuki
    Maejima, Aiko
    Toyoshima, Yuta
    Komiyama, Motokiyo
    Yonemori, Kan
    Yoshida, Akihiko
    Fujimoto, Hiroyuki
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2018, 48 : 1 - 4
  • [8] New Perspectives in the Treatment of Inflammatory Myofibroblastic Tumor with ALK Translocation: Case Report
    Benedetti Pedroza, Johana
    Carrasco Garcia, Irene
    Martinez Bernal, Gala
    Miras Rodriguez, Isabel
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 763 - 772
  • [9] Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report
    Tang, Li-Bo
    Peng, Ying-Long
    Yang, Xiao-Rong
    Li, Jia-Ting
    Lu, Chang
    Zheng, Mei-Mei
    Sun, Lu
    Yang, Zheng
    Yan, Li-Xu
    Deng, Yu
    Chen, Zhi-Hong
    Lv, Si-Di
    Zhou, Qing
    Xu, Chong-Rui
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 631 - 638
  • [10] A Case Report of Epithelioid Inflammatory Myofibroblastic Sarcoma with RANBP2-ALK Fusion Gene Treated with the ALK Inhibitor, Crizotinib
    Kimbara, Shiro
    Takeda, Koji
    Fukushima, Hiroko
    Inoue, Toru
    Okada, Hideaki
    Shibata, Yumi
    Katsushima, Utae
    Tsuya, Asuka
    Tokunaga, Shinya
    Daga, Haruko
    Okuno, Takahiro
    Inoue, Takeshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (09) : 868 - 871
12345